22 aprile 2025 – On 22 April 2025, Ypsomed (SIX:YPSN) announced its sale of Ypsomed Diabetes Care AG, including the relevant subsidiaries, the patch pump development activities and related rights for up to CHF 420 million including earn-out to TecMed AG. The transaction is expected to close in the second half of 2025.

Ypsomed is focusing on strengthening its leading position in the market for subcutaneous self-injection solutions for pharmaceutical and biotech companies. TecMed’s clear vision in diabetes care will reinforce stability for all stakeholders, especially patients, healthcare professionals and employees. TecMed will combine Ypsomed tube pump system mylife Loop, including the mylife YpsoPump and the leading AID solution mylife CamAPS FX, with TecMed’s patch pump program to create a global diabetes care leader fully dedicated on innovative insulin infusion systems.

Walder Wyss advises Ypsomed on the carve-out of the diabetes care business and the sale to TecMed AG. The team is led by Hans-Jakob Diem (Partner, Corporate/M&A) and Dominik Hohler (Partner, Corporate/M&A) and includes Letizia Schlegel (Senior Associate, Corporate/M&A), Michael Kissling (Senior Associate, Corporate/M&A), Arbër Hyseni (Trainee, Corporate/M&A), Michael Isler (Partner, IP/Data Protection and Regulatory) and Kento Reutimann (Associate, IP/Data Protection).